Literature DB >> 22036804

External-beam radiation therapy should be given with androgen deprivation treatment for intermediate-risk prostate cancer: new confirmatory evidence.

Matthew R Cooperberg1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2011        PMID： 22036804      PMCID： PMC3752845          DOI： 10.1038/aja.2011.136

Source DB:  PubMed          Journal:  Asian J Androl        ISSN： 1008-682X            Impact factor:   3.285


× No keyword cloud information.
  14 in total

1.  Radiotherapy and short-term androgen deprivation for localized prostate cancer.

Authors:  Christopher U Jones; Daniel Hunt; David G McGowan; Mahul B Amin; Michael P Chetner; Deborah W Bruner; Mark H Leibenhaut; Siraj M Husain; Marvin Rotman; Luis Souhami; Howard M Sandler; William U Shipley
Journal:  N Engl J Med       Date:  2011-07-14       Impact factor: 91.245

2.  Androgen suppression adjuvant to definitive radiotherapy in prostate carcinoma--long-term results of phase III RTOG 85-31.

Authors:  Miljenko V Pilepich; Kathryn Winter; Colleen A Lawton; Robert E Krisch; Harvey B Wolkov; Benjamin Movsas; Eugen B Hug; Sucha O Asbell; David Grignon
Journal:  Int J Radiat Oncol Biol Phys       Date:  2005-04-01       Impact factor: 7.038

Review 3.  Active surveillance for prostate cancer: progress and promise.

Authors:  Matthew R Cooperberg; Peter R Carroll; Laurence Klotz
Journal:  J Clin Oncol       Date:  2011-08-08       Impact factor: 44.544

4.  External irradiation with or without long-term androgen suppression for prostate cancer with high metastatic risk: 10-year results of an EORTC randomised study.

Authors:  Michel Bolla; Geertjan Van Tienhoven; Padraig Warde; Jean Bernard Dubois; René-Olivier Mirimanoff; Guy Storme; Jacques Bernier; Abraham Kuten; Cora Sternberg; Ignace Billiet; José Lopez Torecilla; Raphael Pfeffer; Carmel Lino Cutajar; Theodore Van der Kwast; Laurence Collette
Journal:  Lancet Oncol       Date:  2010-10-07       Impact factor: 41.316

5.  Metastasis after radical prostatectomy or external beam radiotherapy for patients with clinically localized prostate cancer: a comparison of clinical cohorts adjusted for case mix.

Authors:  Michael J Zelefsky; James A Eastham; Angel M Cronin; Zvi Fuks; Zhigang Zhang; Yoshiya Yamada; Andrew Vickers; Peter T Scardino
Journal:  J Clin Oncol       Date:  2010-02-16       Impact factor: 44.544

6.  Comparative risk-adjusted mortality outcomes after primary surgery, radiotherapy, or androgen-deprivation therapy for localized prostate cancer.

Authors:  Matthew R Cooperberg; Andrew J Vickers; Jeanette M Broering; Peter R Carroll
Journal:  Cancer       Date:  2010-11-15       Impact factor: 6.860

7.  Economic analysis of a phase III clinical trial evaluating the addition of total androgen suppression to radiation versus radiation alone for locally advanced prostate cancer (Radiation Therapy Oncology Group protocol 86-10).

Authors:  Andre Konski; Eric Sherman; Murray Krahn; Karen Bremner; J Robert Beck; Deborah Watkins-Bruner; Michael Pilepich
Journal:  Int J Radiat Oncol Biol Phys       Date:  2005-11-01       Impact factor: 7.038

Review 8.  Higher-than-conventional radiation doses in localized prostate cancer treatment: a meta-analysis of randomized, controlled trials.

Authors:  Gustavo Arruda Viani; Eduardo Jose Stefano; Sergio Luis Afonso
Journal:  Int J Radiat Oncol Biol Phys       Date:  2009-08-01       Impact factor: 7.038

9.  Outcomes of localized prostate cancer following conservative management.

Authors:  Grace L Lu-Yao; Peter C Albertsen; Dirk F Moore; Weichung Shih; Yong Lin; Robert S DiPaola; Michael J Barry; Anthony Zietman; Michael O'Leary; Elizabeth Walker-Corkery; Siu-Long Yao
Journal:  JAMA       Date:  2009-09-16       Impact factor: 56.272

10.  Phase III trial of long-term adjuvant androgen deprivation after neoadjuvant hormonal cytoreduction and radiotherapy in locally advanced carcinoma of the prostate: the Radiation Therapy Oncology Group Protocol 92-02.

Authors:  Gerald E Hanks; Thomas F Pajak; Arthur Porter; David Grignon; Harmart Brereton; Varagur Venkatesan; Eric M Horwitz; Colleen Lawton; Seth A Rosenthal; Howard M Sandler; William U Shipley
Journal:  J Clin Oncol       Date:  2003-11-01       Impact factor: 44.544
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.